All AbMole products are for research use only, cannot be used for human consumption.
MMRi62 is a ferroptosis inducer targeting MDM2-MDM4 (negative regulator of the oncogene p53), which induces ferroptosis accompanied by an increase in reactive oxygen species (ROS) and lysosomal degradation of ferritin heavy chain (FTH1).MMRi62 displays p53-independent apoptosis activity and induces autophagy in pancreatic ductal adenocarcinoma (PDAC) cells. MMRi62 shows p53-independent pro-apoptosis activity and induces autophagy in pancreatic ductal adenocarcinoma (PDAC) cells.) In addition, MMRi62 caused proteasomal degradation of mutant p53 and was active in vivo in an in situ xenograft PDAC mouse model characterized by high-frequency mutations in KRAS and TP53.
| Molecular Weight | 396.27 |
| Formula | C21H15Cl2N3O |
| CAS Number | 352693-80-2 |
| Form | Solid |
| Solubility (25°C) | DMSO 62.5 mg/mL |
| Storage | 4°C, protect from light |
| Related Ferroptosis Products |
|---|
| Cu-ATSM
Cu-ATSM is a copper complex that scavenges free radicals, inhibits lipid peroxidation and ferroptosis. Cu-ATSM exhibits antioxidant, anti-inflammatory and neuroprotective activities. |
| NCOA4-9a
NCOA4-9a (NCOA4-FTH1 inhibitor 9a) is a new ferroptosis inhibitor through disrupting the NCOA4-FTH1 protein-protein interaction, reduces intracellular ferrous iron, inhibits Erastin-induced ferroptosiswith EC50 of 0.29 μM in HT22 cells. |
| HBED
HBED is a potent iron chelator. |
| viFSP1
viFSP1 is a species-independent inhibitor of FSP1 that induces ferroptosis in FSP1-dependent cells. |
| icFSP1
icFSP1 is a potent ferroptosis suppressor protein-1 (FSP1) inhibitor. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
